GlassScriptPhysician profile
Amber Jo Crimes
NPI 1871309427
$433.18
in general payments reported to CMS, 2019-2025
10 companies · $411 in 2025
The $411 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $22.65 · 2025: $411.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $433.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $433.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exeltis, USA INC. | $111.78 | 2024-2025 | Slynd |
| Sage Therapeutics, LLC | $75.62 | 2025 | Zurzuvae |
| Mayne Pharma Commercial LLC | $74.35 | 2025 | |
| Astellas Pharma US INC | $33.13 | 2025 | Veozah |
| Merck Sharp & Dohme LLC | $30.58 | 2025 | Gardasil 9 |
| Vertex Pharmaceuticals Incorporated | $27.62 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $25.14 | 2025 | |
| Hologic Sales and Service, LLC | $24.51 | 2025 | Fetal Fibronectin Enzyme Immunoassay |
| Millicent US INC | $16.93 | 2025 | Femlyv, Intrarosa |
| Abbvie INC. | $13.52 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amber Jo Crimes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.